Skip to main content

Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.

Publication ,  Journal Article
Patel, K; McHutchison, JG
Published in: Postgrad Med
July 2003

Treatment options for chronic HCV infection have evolved significantly over the last few years, and current therapy with pegylated interferon and ribavirin is effective in 50% to 60% of patients with previously untreated infection. Although there is some encouraging progress in new antiviral drug development for hepatitis C, it will be several years before any of these novel compounds are available in clinical practice. In the interim, pegylated interferon and ribavirin remain the cornerstone of therapy. Healthcare providers have an important role in educating and selecting appropriate patients for therapy, recognizing common side effects, establishing a team approach to the management of chronic HCV infection, and keeping abreast of changes in treatment guidelines.

Duke Scholars

Published In

Postgrad Med

DOI

ISSN

0032-5481

Publication Date

July 2003

Volume

114

Issue

1

Start / End Page

48 / 62

Location

England

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Recombinant Proteins
  • RNA, Viral
  • Patient Compliance
  • Interferon Type I
  • Humans
  • Hepatitis C, Chronic
  • Hepacivirus
  • Genotype
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, K., & McHutchison, J. G. (2003). Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. Postgrad Med, 114(1), 48–62. https://doi.org/10.3810/pgm.2003.07.1452
Patel, Keyur, and John G. McHutchison. “Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Postgrad Med 114, no. 1 (July 2003): 48–62. https://doi.org/10.3810/pgm.2003.07.1452.
Patel, Keyur, and John G. McHutchison. “Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Postgrad Med, vol. 114, no. 1, July 2003, pp. 48–62. Pubmed, doi:10.3810/pgm.2003.07.1452.

Published In

Postgrad Med

DOI

ISSN

0032-5481

Publication Date

July 2003

Volume

114

Issue

1

Start / End Page

48 / 62

Location

England

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Recombinant Proteins
  • RNA, Viral
  • Patient Compliance
  • Interferon Type I
  • Humans
  • Hepatitis C, Chronic
  • Hepacivirus
  • Genotype